Accuray (NASDAQ:ARAY) will be posting its quarterly earnings results after the market closes on Tuesday, April 23rd. Analysts expect Accuray to post earnings of ($0.04) per share for the quarter. Accuray has set its FY 2019 guidance at EPS.
Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Tuesday, January 22nd. The medical equipment provider reported ($0.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.03. Accuray had a negative net margin of 5.74% and a negative return on equity of 42.74%. The firm had revenue of $102.32 million for the quarter, compared to analyst estimates of $104.01 million. During the same quarter in the previous year, the firm posted ($0.06) earnings per share. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of ARAY opened at $4.27 on Tuesday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.00 and a current ratio of 1.71. Accuray has a twelve month low of $3.16 and a twelve month high of $5.40. The company has a market capitalization of $386.67 million, a price-to-earnings ratio of -15.25 and a beta of 2.07.
In other Accuray news, CEO Joshua Levine sold 6,604 shares of Accuray stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $4.54, for a total value of $29,982.16. Following the transaction, the chief executive officer now owns 1,033,593 shares of the company’s stock, valued at $4,692,512.22. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 3.40% of the company’s stock.
A hedge fund recently raised its stake in Accuray stock. Geode Capital Management LLC lifted its holdings in Accuray Incorporated (NASDAQ:ARAY) by 14.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 992,090 shares of the medical equipment provider’s stock after purchasing an additional 126,656 shares during the quarter. Geode Capital Management LLC owned 1.13% of Accuray worth $3,382,000 as of its most recent SEC filing. Institutional investors and hedge funds own 80.24% of the company’s stock.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Featured Article: Derivative
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.